An interventional study of HeartMate App-Based Remote Cardiac Rehabilitation Program and Usual Care with HeartMate App-Based rPPG Measurement Only in Cardiovascular Diseases, Heart Failure, Systolic and Coronary Artery Disease, sponsored by Yonsei University. Not yet recruiting. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by Yonsei University · Not applicable, Interventional, and Prevention
This exploratory pilot randomized controlled trial evaluates whether a HeartMate application-based remote patient monitoring (RPM) and digital cardiac rehabilitation program improves cardiovascular, functional, and psychological outcomes in patients with cardiac disease. A total of 200 participants with cardiovascluar disease requiring rehabilitation are randomly assigned in a 1:1 ratio to an intervention group or a control group. The intervention group uses the HeartMate app-based remote cardiac rehabilitation program for 6 weeks, including a daily heart check using smartphone remote photoplethysmography (rPPG), aerobic and resistance exercise, breathing training, and a cognitive-behavioral 'mind' program, with weekly remote coaching. The control group receives usual outpatient care and lifestyle education materials, with the app installed only for rPPG measurement so that digital-biomarker measurement is identical across groups. Clinical assessments (6-minute walk distance, grip strength, blood pressure, blood lipids and metabolic markers), questionnaires (SF-12, PHQ-9, GAD-7, KOSS-24), and digital biomarkers (rPPG-derived heart rate, heart rate variability, respiration, activity) are collected at baseline and at 6 weeks. The primary outcome is the between-group difference in the change in 6-minute walk distance from baseline to 6 weeks. Because this is an exploratory pilot, the results are intended to estimate the effect size and variance for a future definitive randomized controlled trial, and to assess the validity of digital biomarkers as well as the safety, feasibility, and adherence of the program.
Study design: This is a single-center, prospective, open-label, randomized controlled exploratory pilot trial with two parallel groups and 1:1 allocation. A total of 200 participants (100 per group) are planned, with approximately 170 evaluable participants expected after an anticipated 10-20% dropout.
Background and rationale: Traditional hospital-based cardiac rehabilitation has low participation because of travel, time, and cost barriers. Smartphone-based remote patient monitoring and digital cardiac rehabilitation may lower these barriers and enable continuous monitoring of cardiovascular risk factors. Smartphone-derived digital biomarkers, including remote photoplethysmography (rPPG) and heart rate variability (HRV), may provide non-invasive markers correlated with conventional cardiovascular risk indicators.
Randomization: After completion of baseline assessment, participants are randomly allocated 1:1 to the intervention or control group using a random number table with block randomization (block size of 4). The allocation sequence is generated by a person independent of the study, and allocation is concealed using sequentially numbered, password-protected locked files. Investigators performing screening and enrollment do not have access to the allocation sequence.
Intervention group: Participants use the HeartMate app-based remote cardiac rehabilitation program for 6 weeks. The program provides a daily heart check using rPPG, aerobic and resistance exercise, breathing training, and a cognitive-behavioral mind program. Trained staff provide message-based counseling and exercise and lifestyle guidance at least weekly; the Severance research team reviews monitoring logs at least weekly and handles all medical decisions and adverse events.
Control group: Participants receive usual outpatient follow-up and lifestyle education materials. The HeartMate app is installed for rPPG-based measurement only, with no exercise or mind program, so that digital-biomarker measurement is identical across groups and to minimize confounding from app installation.
Assessments: Clinical assessments (6-minute walk distance, grip strength, blood pressure, height, weight, electrocardiogram), blood tests (lipid profile, fasting glucose, renal and hepatic function, electrolytes; HbA1c for participants with diabetes; NT-proBNP for participants with heart failure), questionnaires (SF-12, PHQ-9, GAD-7, KOSS-24), and digital biomarkers (rPPG-derived heart rate, HRV, respiration, activity; reference contact PPG for accuracy verification) are collected at baseline and at 6 weeks. Standardized measurement conditions are applied for rPPG (fasting, seated stable posture, camera distance 30-50 cm, uniform lighting, repeated measurement, and signal-quality control).
Outcomes: The primary outcome is the between-group difference in the change in 6-minute walk distance from baseline to 6 weeks, analyzed primarily by independent-samples t-test (exploratory) with ANCOVA as a supportive analysis adjusting for baseline and covariates. Secondary outcomes include safety (adverse events and serious adverse events) and adherence (app usage days and target usage rate of at least 80%). Exploratory outcomes include changes in blood pressure, blood lipids, glucose and HbA1c, quality of life and psychological measures, and the agreement between rPPG-derived and reference contact-PPG digital biomarkers.
Statistical considerations: As an exploratory pilot, the sample size is intended to provide reliable preliminary estimates (effect size, standard deviation, dropout rate) for a future definitive randomized controlled trial rather than to confirm efficacy. Analyses follow the intention-to-treat principle, with missing data handled per the statistical analysis plan.
Data management: Data are identified only by a unique subject code and stored on an encrypted secure server (AES-256 encryption; FIPS 140-3 physical and logical security). rPPG facial video is not stored; only de-identified RGB time-series signals are retained. Records are kept for 3 years after study completion and then destroyed irrecoverably.
4,904 studies on the registry are indexed under Cardiovascular Diseases; 919 are open to participants now.
This study's planned enrollment of 200 is above the median of 100 across 2,738 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Yonsei University is the lead sponsor of 1,387 studies on the registry; 232 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants use the HeartMate app-based remote cardiac rehabilitation program for 6 weeks (daily rPPG heart check; aerobic and resistance exercise; breathing training; cognitive-behavioral mind program), with at least weekly remote coaching.
Device: HeartMate App-Based Remote Cardiac Rehabilitation Program
Participants receive usual outpatient follow-up and lifestyle education materials. The HeartMate app is installed for rPPG-based measurement only (no exercise or mind program) to keep digital-biomarker measurement identical across groups.
Device: Usual Care with HeartMate App-Based rPPG Measurement Only
A 6-week smartphone application program delivering a daily heart check using remote photoplethysmography (rPPG), aerobic and resistance exercise, breathing training, and a cognitive-behavioral mind program. Trained staff provide message-based counseling and exercise/lifestyle guidance at least weekly, and the Severance research team reviews monitoring logs at least weekly and handles all medical decisions and adverse events.
Standard outpatient follow-up and lifestyle education materials without the exercise or mind program. The HeartMate app is installed solely for rPPG-based digital-biomarker measurement at baseline and at 6 weeks, ensuring identical measurement conditions across groups.
Change from Baseline in 6-Minute Walk Test (6MWT) Distance at 6 Weeks
The distance walked (in meters) during the 6-minute walk test, measured at baseline and at 6 weeks. The change (Week 6 minus baseline) is compared between the intervention and control groups. As an exploratory pilot outcome, the primary purpose is to estimate the effect size and standard deviation for a future randomized controlled trial rather than to confirm efficacy.
Time frame: Baseline and 6 weeks (change from baseline to Week 6)
Number of Participants With At Least One Adverse Event (AE)
Number of participants with at least one adverse event during the intervention period. Unit of measure: participants (count).
Time frame: From randomization through 6 weeks
Number of Participants With At Least One Serious Adverse Event (SAE)
Number of participants with at least one serious adverse event during the intervention period. Unit of measure: participants (count).
Time frame: From randomization through 6 weeks
Proportion of Participants Achieving Target Application Usage (>= 80%)
Percentage of intervention-group participants whose HeartMate application usage reaches at least 80% of the prescribed daily sessions. Unit of measure: percentage of participants (%). A higher value indicates better adherence.
Time frame: Over the 6-week intervention period
Change From Baseline in Systolic Blood Pressure at 6 Weeks
Change from baseline to 6 weeks in resting systolic blood pressure, measured after 5 minutes of rest using an automated sphygmomanometer. Unit of measure: mmHg.
Time frame: Baseline and 6 weeks
Change From Baseline in Diastolic Blood Pressure at 6 Weeks
Change from baseline to 6 weeks in resting diastolic blood pressure, measured after 5 minutes of rest using an automated sphygmomanometer. Unit of measure: mmHg.
Time frame: Baseline and 6 weeks
Change From Baseline in Total Cholesterol at 6 Weeks
Change from baseline to 6 weeks in serum total cholesterol. Unit of measure: mg/dL.
Time frame: Baseline and 6 weeks
Change From Baseline in LDL Cholesterol at 6 Weeks
Change from baseline to 6 weeks in serum low-density lipoprotein (LDL) cholesterol. Unit of measure: mg/dL.
Time frame: Baseline and 6 weeks
Change From Baseline in HDL Cholesterol at 6 Weeks
Change from baseline to 6 weeks in serum high-density lipoprotein (HDL) cholesterol. Unit of measure: mg/dL.
Time frame: Baseline and 6 weeks
Change From Baseline in Triglycerides at 6 Weeks
Change from baseline to 6 weeks in serum triglycerides. Unit of measure: mg/dL.
Time frame: Baseline and 6 weeks
Change From Baseline in Fasting Plasma Glucose at 6 Weeks
Change from baseline to 6 weeks in fasting plasma glucose. Unit of measure: mg/dL.
Time frame: Baseline and 6 weeks
Change From Baseline in Glycated Hemoglobin (HbA1c) at 6 Weeks
Change from baseline to 6 weeks in glycated hemoglobin (HbA1c). Unit of measure: percent (%).
Time frame: Baseline and 6 weeks
Change From Baseline in SF-12 Physical Component Summary at 6 Weeks
Change from baseline to 6 weeks in the Physical Component Summary (PCS) of the 12-Item Short-Form Health Survey (SF-12). Scores range from 0 to 100; higher scores indicate better physical health-related quality of life. Unit of measure: units on a scale. (The exact minimum and maximum depend on the SF-12 scoring algorithm used.)
Time frame: Baseline and 6 weeks
Change From Baseline in SF-12 Mental Component Summary at 6 Weeks
Change from baseline to 6 weeks in the Mental Component Summary (MCS) of the 12-Item Short-Form Health Survey (SF-12). Scores range from 0 to 100; higher scores indicate better mental health-related quality of life. Unit of measure: units on a scale. (The exact minimum and maximum depend on the SF-12 scoring algorithm used.)
Time frame: Baseline and 6 weeks
Change From Baseline in PHQ-9 Total Score at 6 Weeks
Change from baseline to 6 weeks in the Patient Health Questionnaire-9 (PHQ-9) total score. Total score ranges from 0 to 27; higher scores indicate more severe depressive symptoms (a worse outcome). Unit of measure: units on a scale.
Time frame: Baseline and 6 weeks
Change From Baseline in GAD-7 Total Score at 6 Weeks
Change from baseline to 6 weeks in the Generalized Anxiety Disorder-7 (GAD-7) total score. Total score ranges from 0 to 21; higher scores indicate more severe anxiety symptoms (a worse outcome). Unit of measure: units on a scale.
Time frame: Baseline and 6 weeks
Change From Baseline in KOSS-SF Total Score at 6 Weeks
Change from baseline to 6 weeks in the Korean Occupational Stress Scale - Short Form (KOSS-SF, 24 items). Item scores are converted to a 0 to 100 scale; higher scores indicate greater occupational stress (a worse outcome). Unit of measure: units on a scale.
Time frame: Baseline and 6 weeks
Mean Absolute Error Between rPPG- and Reference Contact PPG-Derived Heart Rate
Mean absolute error between heart rate derived from smartphone remote photoplethysmography (rPPG) and simultaneously measured reference contact PPG. Unit of measure: beats per minute (bpm). Lower values indicate better agreement.
Time frame: Baseline and 6 weeks
Correlation Between rPPG- and Reference Contact PPG-Derived HRV (SDNN)
Pearson correlation coefficient between heart rate variability (SDNN) derived from rPPG and from reference contact PPG. Unit of measure: correlation coefficient (r), ranging from -1 to 1; values closer to 1 indicate better agreement.
Time frame: Baseline and 6 weeks
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yonsei University